Hence, we present a case of an RET fusion-positive, stage IIIA NSCLC patient who progressed on chemotherapy and subsequently received preoperative selpercatinib treatment, achieving major pathological response (MPR). This evidence concerns the gene RET and non-small cell lung carcinoma.